Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Respiratory syncytial virus vaccine – Epidemiology – Epidemiology- Respiratory Syncytial Virus Vaccine- Mature Markets

Login to access report north_east
Contact sales account_box

Clarivate Epidemiology’s coverage of the RSV vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the population recommended to receive the RSV vaccine for each country, as well as annualized case counts projected to the national population.

All patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s RSV vaccine forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of the RSV vaccine-eligible population over the forecast period?

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate’s Epidemiology forecasts six RSV vaccine patient populations, as follows:

  • Pediatric population eligible for the RSV vaccine.
  • Adult population eligible for the RSV vaccine.
  • Maternal population eligible for the RSV vaccine.
  • Pediatric population newly eligible for the RSV vaccine.
  • Adult population newly eligible for the RSV vaccine.
  • Maternal population newly eligible for the RSV vaccine.

Note: Coverage may vary by country and region.

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Human Immunodeficiency Virus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Human Immunodeficiency Virus (US)
The HIV therapy market is crowded with several approved ARVs. Market growth is driven by the increasing acceptance of new, high-priced ARVs, particularly the latest STRs, which offer improved…
north_east
Report
Squamous Cell Carcinoma of the Head and Neck – Geographic Focus: China – China In-Depth – Squamous Cell Carcinoma of the Head and Neck
China’s SCCHN market is undergoing rapid transformation, driven by the expanding use of systemic therapies beyond traditional surgery and radiotherapy. Current treatment options include…
north_east
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
north_east
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Geographic Focus: China – Bladder Cancer and Upper Tract Urothelial Carcinoma – China In-Depth – China
China’s bladder cancer market is entering a period of accelerated expansion, as novel branded therapies reshape systemic management. A major growth driver is the expanding role of immune…
north_east
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a widely drug-treated condition managed with multiple drug classes, most commonly selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east